Clostridium difficile infection is four times more likely to kill patients with inflammatory bowel disease, suggests research published ahead of print in the journal Gut. C difficile is an important cause of diarrhea among inpatients, and the numbers of new cases of the infection have been steadily increasing in recent years.
The findings are based on a representative sample of community hospital admissions in the U.S. for 2003.
The sample covered 994 hospitals in 37 States and included a total of 124,570 patients. Of these, 44,400 had been admitted with C difficile infection, and 77,366 had been admitted with inflammatory bowel disease (Crohns disease or ulcerative colitis), or IBD for short. A further 2,804 had both IBD and C difficile infection. Those with the infection alone tended to be considerably older, and had an average age of 73. Those with IBD had an average age of 42.
The risk of death was higher among those with C difficile infection alone or in combination with IBD than it was in those with IBD alone. But patients with both the infection and IBD were four times more likely to die than patients with just IBD or C difficile infection alone, irrespective of age.
Patients with the combination also stayed in hospital three days longer and had higher rates of endoscopy, a procedure in which a long tube with a camera on the end is passed through the gut. Patients with ulcerative colitis had more severe C difficile infection than those with Crohns disease and worse outcomes.
The authors conclude that patients with IBD may be particularly susceptible to infection with C difficile.
Reference: Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Online First Gut 2007.
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.